Crosslinked coatings delivered by a balloon

Patent metadata

Field	Value
Publication number	US-9694112-B2
Application number	US-201514965387-A
Country	US
Kind code	B2
Filing date	Dec 10, 2015
Priority date	Mar 15, 2013
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

The present invention relates to systems for and corresponding methods of delivering a therapeutic agent to a vessel wall of a body lumen by providing a compound capable of being crosslinked after intraluminal release onto a vessel wall so that the therapeutic agent is temporarily retained at the site of delivery by the crosslinked compound.

First claim

What is claimed is:

1. A system to deliver a therapeutic agent to a vessel wall of a body lumen, comprising:
(a) an expandable member having a distal end, a proximal end and a working length therebetween;
(b) a crosslinkable compound disposed along at least a portion of the working length for intraluminal release therefrom after expansion of the expandable member, the crosslinkable compound that is crosslinked by a solvent to form a crosslinked formulation after intraluminal release to a vessel wall;
(c) at least one therapeutic agent disposed along at least a portion of the working length; and
(d) a crosslinking source configured to release the solvent to the crosslinkable compound to form the crosslinked formulation after intraluminal release to the vessel wall, the crosslinked formulation retaining the at least one therapeutic agent to the vessel wall.

2. The system of claim 1 , wherein the crosslinkable compound is disposed as a coating on the expandable member.

3. The system of claim 1 , wherein the expandable member comprises an outer surface with reservoirs defined therein along the portion of the working length, and the crosslinkable compound is disposed for intraluminal release within the reservoirs.

4. The system of claim 1 , wherein the expandable member comprises pores defined therein along the portion of the working length, and the crosslinkable compound is disposed for intraluminal release through the pores.

5. The system of claim 1 , wherein the at least one therapeutic agent is combined with the crosslinkable compound.

6. The system of claim 1 , wherein the crosslinkable compound is selected from the group consisting of poly(ester amide), PLGA, PDLLA, PLLA, PLGA-PEG-PLGA, PLLA-PEG-PLLA, and combinations thereof.

7. The system of any one of claim 1 , wherein the at least one therapeutic agent is selected from the group consisting of antithrombotics, anticoagulants, antiplatelet agents, anti-lipid agents, thrombolytics, antiproliferatives, anti-inflammatories, agents that inhibit hyperplasia, smooth muscle cell inhibitors, antibiotics, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters, antimitotics, antifibrins, antioxidants, antineoplastics, agents that promote endothelial cell recovery, antiallergic substances, viral vectors, nucleic acids, monoclonal antibodies, antisense compounds, oligonucleotides, cell permeation enhancers, radiopaque agent markers, HMG CoA reductase inhibitors, pro-drugs, and combinations thereof.

8. A method of delivering a therapeutic agent to a vessel wall of a body lumen, comprising:
providing a system including (a) an expandable member having a distal end, a proximal end and a working length therebetween, (b) a crosslinkable compound disposed along at least a portion of the working length of the expandable member, (c) at least one therapeutic agent disposed along at least a portion of the working length, and (d) a crosslinking source configured to release a solvent to the crosslinkable compound to form a crosslinked formulation after intraluminal release to the vessel wall, the crosslinked formulation retaining the at least one therapeutic agent to the vessel wall;
positioning the expandable member in a body lumen;
expanding the expandable member to contact the vessel wall for intraluminal release of the crosslinkable compound and the at least one therapeutic agent from the expandable member to the vessel wall; and
forming a crosslinked formulation from the crosslinkable compound with the solvent after intraluminal release to the vessel wall by releasing the solvent released from the crosslinking source, the crosslinked formulation retaining the at least one therapeutic agent to the vessel wall.

9. The system of claim 2 , wherein the coating includes an outer layer comprising the at least one therapeutic agent.

10. The system of claim 3 , wherein the at least one therapeutic agent is disposed for intraluminal release from the reservoirs.

11. The system of claim 4 , wherein the at least one therapeutic agent is disposed for intraluminal release through the pores.

12. The system of claim 1 , wherein the solvent is selected from the group consisting of N-methypyrrolidinone, dimethyl sulfoxide, dichloromethane, and combinations thereof.

13. The method of claim 8 , wherein the crosslinkable compound is disposed as a coating on the expandable member.

14. The method of claim 13 , wherein the coating includes an outer layer comprising the at least one therapeutic agent.

15. The method of claim 8 , wherein the expandable member comprises an outer surface with reservoirs defined therein along the portion of the working length, and the crosslinkable compound is disposed for intraluminal release within the reservoirs.

16. The method of claim 8 , wherein the expandable member comprises pores defined therein along the portion of the working length, and the crosslinkable compound is disposed for intraluminal release through the pores.

17. The method of claim 8 , wherein the at least one therapeutic agent is combined with the crosslinkable compound.

18. The method of claim 8 , wherein the crosslinkable compound is selected from the group consisting of poly(ester amide), PLGA, PDLLA, PLLA, PLGA-PEG-PLGA, PLLA-PEG-PLLA, and combinations thereof.

19. The method of claim 8 , wherein the at least one therapeutic agent is selected from the group consisting of antithrombotics, anticoagulants, antiplatelet agents, anti-lipid agents, thrombolytics, antiproliferatives, anti-inflammatories, agents that inhibit hyperplasia, smooth muscle cell inhibitors, antibiotics, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters, antimitotics, antifibrins, antioxidants, antineoplastics, agents that promote endothelial cell recovery, antiallergic substances, viral vectors, nucleic acids, monoclonal antibodies, antisense compounds, oligonucleotides, cell permeation enhancers, radiopaque agent markers, HMG CoA reductase inhibitors, pro-drugs, and combinations thereof.

20. The method of claim 8 , wherein the solvent is selected from the group consisting of N-methypyrrolidinone, dimethyl sulfoxide, dichloromethane, and combinations thereof.

Assignees

• Abbott Cardiovascular Systems Inc

Inventors

• Stankus John
• Trollsas Mikael
• Hossainy Syed

Classifications

• A61M2025/105

  having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes · CPC title

• A61M25/1006

  Balloons formed between concentric tubes · CPC title

• A61L29/085 Primary

  Macromolecular materials · CPC title

• A61L31/16 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61F2/82

  Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07) · CPC title